RxDoctor Payments Data

Stephen Humble, MD

Psychiatry · Nashville, TNNPI 1609931799

Payments from drug & device makers

$1,519in general payments, 2019–2025

Across 35 payments — averaging $43.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$374
  • Axsome Therapeutics, Inc.$333
  • Sunovion Pharmaceuticals Inc.$213
  • E.r. Squibb & Sons, L.L.C.$146
  • Neurocrine Biosciences, Inc.$121
  • Teva Pharmaceuticals USA, Inc.$118
  • plus $214 from 4 others

What the payments were for

  • Food & beverage$1,48998%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,519 in reported general payments places this provider in the 70th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,223
Medicare patients
31
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$150,676
AuvelityDextromethorphan Hbr/Bupropion114$140,364
VraylarCariprazine Hcl42$61,149
Bupropion XlBupropion Hcl194$6,771
BelsomraSuvorexant11$4,472
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$4,245
Trazodone Hcl143$2,862
Lurasidone Hcl16$2,002
Dextroamphetamine Sulfate13$1,872
Doxepin Hcl99$1,473
Duloxetine Hcl47$1,371
Quetiapine Fumarate43$1,233
Mirtazapine79$1,195
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$997
Lamotrigine85$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$118$150,67614 claims
Axsome Therapeutics, Inc.Auvelity$333$140,364114 claims
AbbVieVraylar$374$61,14942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →